FDA grants priority review to BeOne’s BRUKINSA‑rituximab regimen for first‑line mantle cell lymphoma
The U.S. Food and Drug Administration accepted BeOne Medicines’ supplemental NDA and assigned priority review to the combination of BRUKINSA (zanubrutinib) with rituximab for adults with newly diagnosed mantle‑cell lymphoma. The decision is based on the Phase 3 MANGROVE trial, which showed a 43 % relative reduction in the risk of disease progression or death compared with bendamustine‑rituximab. The company has also filed parallel applications with the European Medicines Agency and China’s NMPA.
Why it matters
The priority‑review status shortens the FDA’s evaluation timeline, potentially bringing a chemotherapy‑free first‑line option to market sooner, which could boost BeOne’s sales and market share. Investors will watch the FDA’s final decision and the upcoming data presentation at the American Society of Hematology meeting for further clues on approval likelihood.
Key facts
- 1The FDA granted priority review to BeOne’s supplemental NDA for the BRUKINSA‑rituximab regimen on 4 Nov 2026. investing.com
- 2The MANGROVE study enrolled 510 patients at 157 clinical sites worldwide. chathamdailynews.ca
- 3The trial reported a hazard ratio of 0.57 with a 95 % confidence interval of 0.43‑0.76 for progression‑free survival. finance.yahoo.com
- 4Patients receiving the BRUKINSA‑rituximab combination experienced a 43 % lower risk of progression or death versus the bendamustine‑rituximab arm. chathamdailynews.ca
- 5Full trial results are scheduled for presentation at the 68th American Society of Hematology Annual Meeting on 13 Dec 2026. finance.yahoo.com
- 6BeOne has also submitted regulatory dossiers for the same indication to the EMA and China’s NMPA. investing.com
Summary written by AlphAI AI Desk from 3 of 3 sources. Not investment advice. Figures are as stated by the linked sources.